Related Experiment Video
Updated: Sep 25, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
TNF inhibitors: a review of the recent patent literature
1Celltech Group Ltd, Granta Park, Cambridge, CB1 6GS, UK. bobwatson@cam.celltechgroup.com
Abstract:
Overproduction of the inflammatory cytokine tumor necrosis factor (TNF)-alpha is implicated in a wide range of pathological conditions, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis and stroke. This review focuses on recent developments in the patent literature, which are aimed principally at the suppression of TNF release. The review will separately detail the development of biological agents, such as soluble TNF receptors and engineered antibodies, and small molecules, which primarily target TNF.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Biopharmaceutical Factors Influencing Drug Product Design: Overview
